Covid vaccine manufacturer Moderna has completed a new site in the UK, which it says will help prepare the the country ...

The decline in spending on respiratory programs was partly offset by increased investment in the individualized neoantigen therapy mRNA-4157 and norovirus programs. Moderna said the FDA has lifted ...

This reduction was partially offset by increased investment in Moderna's individualized neoantigen therapy (mRNA-4157), which has been assigned the generic name intismeran autogene, and norovirus ...

Moderna's respiratory vaccine sales are not ... Stage 3 efficacy outcomes and further R&D cycles could impact its overall prospects. Norovirus vaccine trials are also in Phase 3, with similar ...